Shobhit Baijal
Birmingham, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.
Journal: Lung cancer management
Published: July 21, 2026
Severe Toxic Epidermal Necrolysis Following Combination Ipilimumab-Nivolumab Therapy for Pleural Mesothelioma, Successfully Treated With Ruxolitinib: A Case Report.
Journal: Clinical lung cancer
Published: February 06, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
Journal: JTO clinical and research reports
Published: October 21, 2025
Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer.
Journal: Acta oncologica (Stockholm, Sweden)
Published: July 11, 2025
Curative-Intent Multimodality Treatment for NSCLC: Will Global Healthcare Systems Rise to the Challenge? A Perspective From the United Kingdom.
Journal: JTO clinical and research reports
Published: May 16, 2025
Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England.
Journal: Clinical lung cancer
Published: October 05, 2024
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial.
Journal: JTO clinical and research reports
Published: July 16, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2024
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101.
Journal: The oncologist
Published: February 02, 2024
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.
Journal: Targeted oncology
Published: January 27, 2024
Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK.
Journal: The oncologist
Published: October 26, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
Journal: Clinical lung cancer
Published: December 16, 2021
Last Updated: 09/26/2026